Medicare Denies Full Coverage for Studies on PET BetaAmyloid Imaging but Covers One Scan Per Patient for Further Research

“There is sufficient evidence to suggest that PET beta-amyloid imaging could be used to exclude Alzheimer’s disease in narrowly defined and clinically difficult differential diagnoses, such as Alzheimer’s disease versus frontotemporal dementia. ” PET beta-amyloid imaging could potentially be used as a diagnostic tool when it comes to differentiating between Alzheimers and other similar diseases. While Medicare has stated that the current data is inconclusive and they will not cover any comprehensive studies at this time, they concede that this technique could be highly valuable for Alzheimer’s patients in the future and are covering one scan per patient in a clinical trial.